MD
Pediatrix Medical Group, Inc.
MD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MD overall, supported by stronger fundamentals and stronger modeled upside.
MD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
MD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $19.61 | -38% |
| Fair | 13x | $23.57 | -25% |
| Forward | 13x | $31.40 | — |
| Current | 17x | $31.40 | — |
| Expensive | 19x | $34.33 | +9.3% |
Historical ranges are pointers, not guarantees.
MD's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MD in the historical PE scenario, which offers more potential upside but is not a forecast.
MD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MD's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MD on the outlook, with more favorable revenue expectations.
MD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.45 | +33% |
| Q3 2026 | $1.84 | -3.7% |
| Q2 2026 | $2.09 | +61% |
| Q1 2026 | $2.06 | +$3.06 |
| Q4 2025 | $1.94 | +$3.13 |
| Q3 2025 | $1.91 | +$4.97 |
| Q2 2025 | $1.30 | +$4.33 |
| Q1 2025 | -$1.00 | -$0.15 |
| Q4 2024 | -$1.19 | -$0.46 |
MD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $501.4M | +1.7% |
| Q2 2026 | $487.8M | +4% |
| Q1 2026 | $476.2M | +3.9% |
| Q4 2025 | $493.8M | -1.7% |
| Q3 2025 | $492.9M | -3.6% |
| Q2 2025 | $468.8M | -7% |
| Q1 2025 | $458.4M | -7.4% |
| Q4 2024 | $502.4M | +1.2% |
MD's revenue fell from its 2019 peak and has held roughly level since: $501M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.8 points |
| Q2 2026 | 12% | -1.1 points |
| Q1 2026 | 8.8% | +1.8 points |
| Q4 2025 | 9.9% | +2.1 points |
| Q3 2025 | 14% | +7.2 points |
| Q2 2025 | 13% | +44 points |
| Q1 2025 | 7% | +3.8 points |
| Q4 2024 | 7.8% | +30 points |
MD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $112.9M | -14% |
| Q2 2026 | $123.9M | -6.6% |
| Q1 2026 | -$136.1M | -$15.3M |
| Q4 2025 | $108.8M | -16% |
| Q3 2025 | $131.9M | +54% |
| Q2 2025 | $132.7M | +33% |
| Q1 2025 | -$120.8M | +$9.8M |
| Q4 2024 | $129.6M | +115% |
MD still generates free cash flow, though less than at its 2020 peak: $210M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MD on cash flow, with more consistent year-over-year improvement.
MD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -1.7M shares |
| 1 year | -6.9% | -5.9M shares |
| 3 years | -3.9% | -3.2M shares |
| 5 years | -7.4% | -6.4M shares |
| Available history | -4.3% | -3.6M shares |
MD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $83M |
| Q2 2026 | $42.7M |
| Q1 2026 | $21.5M |
| Q4 2025 | $64M |
| Q3 2025 | $20.9M |
| Q2 2025 | $209,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $643,000 |
MD spent $211M buying back its own shares over the past year, about nine times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 2.0x | Moderate |
| Q1 2024 | 2.9x | Moderate |
| Q4 2023 | 12.9x | High |
MD's net debt is about 1.1 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MD on leverage, with a lower net debt burden relative to earnings.
MD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.7 | Overbought |
| Stochastic | 80.5 | Overbought |
MD's weekly RSI is 78 (overbought) and its Stochastic is 81 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MD PE vs Healthcare Sector
| Metric | MD | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 72 | 29 | 43 pts above |
MD is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MD on valuation relative to its sector.
MD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 10% above |
| 20 week MA | $27.3 | 15% above |
| 50 week MA | $24.0 | 31% above |
| 100 week MA | $19.6 | 60% above |
| 200 week MA | $15.6 | 101% above |
MD is in an uptrend: it's above all five of its weekly moving averages, and 101% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.2 | $23.9 | -12% |
| 2021 | $23.9 | $27.6 | +15% |
| 2022 | $27.6 | $14.9 | -46% |
| 2023 | $14.9 | $9.30 | -38% |
| 2024 | $9.30 | $13.5 | +45% |
| 2025 | $13.5 | $21.9 | +62% |
| 2026 YTD | $21.9 | $31.4 | +44% |
MD is up 44% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MD on returns for 2026, with the stronger performance.